UroGen Pharma (URGN) Other financing activities (2019 - 2026)
UroGen Pharma (URGN) posted Other financing activities of $179000.0 for Q1 2026, up 6066.67% on a QoQ basis from -$3000.0 in Q4 2025, and up 496.67% year-over-year from $30000.0 in Q1 2025.
UroGen Pharma (URGN) Other financing activities (2019 - 2026) Analysis & Trends
UroGen Pharma's Other financing activities history runs 8 years deep, the most recent figure standing at $179000.0 for Q1 2026.
- Quarterly Other financing activities rose 496.67% year-over-year to $179000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149000.0 (down 99.2% YoY) and the FY2024 annual result came in at $18.6 million, up 2035.28% from the prior year.
- Other financing activities was $179000.0 for Q1 2026 at UroGen Pharma, up from -$3000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $47.9 million in Q3 2023 and bottomed at -$47.8 million in Q4 2023.
- A 5-year average of $1.6 million and a median of $143000.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities soared 37133.33% — and 2023, when it slumped 12752.65%.
- UroGen Pharma's Other financing activities stood at $378000.0 in 2022, then sank by 12752.65% to -$47.8 million in 2023, then surged by 138.69% to $18.5 million in 2024, then slumped by 100.02% to -$3000.0 in 2025, then soared by 6066.67% to $179000.0 in 2026.
- Business Quant data shows URGN's Other financing activities at $179000.0 in Q1 2026, -$3000.0 in Q4 2025, and -$27000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179,000.00 |
| Mar 31, 2026 | 179,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Jun 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -27,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Sep 30, 2024 | 18.51 Mn |
| Sep 30, 2024 | 18.51 Mn |
| Jun 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 135,000.00 |
| Dec 31, 2023 | -47.83 Mn |
| Dec 31, 2023 | -47.83 Mn |
| Sep 30, 2023 | 47.89 Mn |
| Sep 30, 2023 | 47.89 Mn |
| Jun 30, 2023 | 143,000.00 |
| Jun 30, 2023 | 143,000.00 |
| Mar 31, 2023 | 671,000.00 |
| Mar 31, 2023 | 671,000.00 |